

References

- Andersson, H., Kaplan, P., Kacena, K., & Yee, J. (2008). Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. *Pediatrics*, *122*(6), 1182–1190.
- Aubourg, P. (2007). Axons need glial peroxisomes. *Nature Genetics*, *39*(8), 936–938.
- Aubourg, P., Blanche, S., Jambaque, I., Rocchiccioli, F., Kalifa, G., & Naud-Saudreau, C., et al. (1990). Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. *The New England Journal of Medicine*, *322*(26), 1860–1866.
- Baes, M., & Aubourg, P. (2009). Peroxisomes, myelination, and axonal integrity in the CNS. *Neuroscientist*, *15*(4), 367–379.
- Baes, M., Gressens, P., Huyghe, S., De, N. K., Qi, C., & Jia, Y., et al. (2002). The neuronal migration defect in mice with Zellweger syndrome (Pex5 knockout) is not caused by the inactivity of peroxisomal beta-oxidation. *Journal of Neuropathology and Experimental Neurology*, *61*(4), 368–374.
- Bayever, E., August, C. S., Kamani, N., Ferreira, P., Wenger, D., & Krivit, W. (1992). Allogeneic bone marrow transplantation for Niemann-Pick disease (type IA). *Bone Marrow Transplant*, *10*(Suppl. 1), 85–86.
- Bayever, E., Kamani, N., Ferreira, P., Machin, G. A., Yudkoff, M., & Conard, K., et al. (1992). Bone marrow transplantation for Niemann-Pick type IA disease. *Journal of Inherited Metabolic Disease*, *15*(6), 919–928.
- Biffi, A., De Palma, M., Quattrini, A., Del Carro, U., Amadio, S., & Visigalli, I., et al. (2004). Correction of metachromatic leukodystrophy in the mouse model by transplantation of

- genetically modified hematopoietic stem cells. *Journal of Clinical Investigation*, 113(8), 1118–1129.
- Bourgeron, T., Rustin, P., Chretien, D., Birch-Machin, M., Bourgeois, M., & Viegas-Pequignot, E., et al. (1995). Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. *Nature Genetics*, 11, 144–149.
- Brady, R. O. (2006). Enzyme replacement for lysosomal diseases. *Annual Review of Medicine*, 57, 283–296.
- Brites, P., Mooyer, P. A., El Mrabet, L., Waterham, H. R., & Wanders, R. J. (2009). Plasmalogens participate in very-long-chain fatty acid-induced pathology. *Brain*, 132(Pt 2), 482–492.
- Brown, A. M., & Ransom, B. R. (2007). Astrocyte glycogen and brain energy metabolism. *Glia*, 55(12), 1263–1271.
- Cachon-Gonzalez, M. B., Wang, S. Z., Lynch, A., Ziegler, R., Cheng, S. H., & Cox, T. M. (2006). Effective gene therapy in an authentic model of Tay-Sachs-related diseases. *Proceedings of the National Academy of Sciences of the United States of America*, 103(27), 10373–10378.
- Chang, C. C., South, S., Warren, D., Jones, J., Moser, A. B., & Moser, H. W., et al. (1999). Metabolic control of peroxisome abundance. *Journal of Cell Science*, 112(Pt 10), 1579–1590.
- Conradi, N. G., Sourander, P., Nilsson, O., Svennerholm, L., & Erikson, A. (1984). Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies. *Acta Neuropathologica*, 65(2), 99–109.
- Consiglio, A., Quattrini, A., Martino, S., Bensadoun, J. C., Dolcetta, D., & Trojani, A., et al.

- (2001). *In vivo* gene therapy of metachromatic leukodystrophy by lentiviral vectors: Correction of neuropathology and protection against learning impairments in affected mice. *Nature Medicine*, 7(3), 310–316.
- Crocker, A. C. (1961). The cerebral defect in Tay-Sachs disease and Niemann-Pick disease. *Journal of Neurochemistry*, 7, 69–80.
- De Duve, C., & Baudhuin, P. (1966). Peroxisomes (microbodies and related particles). *Physiological Reviews*, 46(2), 323–357.
- De Meileir, L. (2002). Defects of pyruvate metabolism and the Krebs cycle. *Journal of Child Neurology*, 17, S26–S33.
- De Meirleir, L., Seneca, S., Lissens, W., De Clercq, I., Eyskens, F., & Gerlo, E. (2004). Respiratory chain complex V deficiency due to a mutation in the assembly gene ATP12. *Journal of Medical Genetics*, 41(2), 120–124.
- De Vivo, D. C., Trifiletti, R. R., Jacobson, R. I., Ronen, G. M., Behmand, R. A., & Harik, S. I. (1991). Defective glucose transport across the blood–brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. *The New England Journal of Medicine*, 325(10), 703–709.
- De Vivo, D. C., Wang, D., & Pascual, J. (2008). Disorders of glucose transport. In S. D. R. N. Rosenberg, H. L. Paulson, L. Ptáček & E. J. Nestler (Eds.), *The molecular and genetic basis of neurological disease* (pp. 653–661). Philadelphia: Lippincott Williams & Wilkins.
- Desnick, R. J., & Schuchman, E. H. (2002). Enzyme replacement and enhancement therapies: Lessons from lysosomal disorders. *Nature Reviews Genetics*, 3(12), 954–966.
- DiDonato, S., & Taroni, F. (2008). Disorders of lipid metabolism. In R. N. Rosenberg (Ed.), *The*

- molecular and genetic basis of neurologic and psychiatric disease* (pp. 610–623). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins.
- DiMauro, S., & Bonilla, E. (2004). Mitochondrial encephalomyopathies. In A. G. Engel & C. Franzini-Armstrong (Eds.), *Myology* (pp. 1623–1662). New York: McGraw-Hill.
- DiMauro, S., & Schon, E. A. (2003). Mitochondrial respiratory-chain diseases. *The New England Journal of Medicine*, *348*, 2656–2668.
- Dutsch, M., & Hilz, M. J. (2010). Neurological complications in Fabry disease. *La Revue de Medecine Interne*, *31*(Suppl. 2), S243–S250.
- Dwek, R. A., Butters, T. D., Platt, F. M., & Zitzmann, N. (2002). Targeting glycosylation as a therapeutic approach. *Nature Reviews Drug Discovery*, *1*(1), 65–75.
- Escobar, M. L., Poe, M. D., Provenzale, J. M., Richards, K. C., Allison, J., & Wood, S., et al. (2005). Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. *The New England Journal of Medicine*, *352*(20), 2069–2081.
- Espeel, M., Depreter, M., Nardacci, R., D'Herde, K., Kerckaert, I., & Stefanini, S., et al. (1997). Biogenesis of peroxisomes in fetal liver. *Microscopy Research and Technique*, *39*(5), 453–466.
- Fahimi, H. D., & Baumgart, E. (1999). Current cytochemical techniques for the investigation of peroxisomes. A review. *The Journal of Histochemistry and Cytochemistry*, *47*(10), 1219–1232.
- Fan, J. Q., & Ishii, S. (2007). Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. *The FEBS Journal*, *274*(19), 4962–4971.
- Faust, P. L., Kaye, E. M., & Powers, J. M. (2010). Myelin lesions associated with lysosomal and peroxisomal disorders. *Expert Review of Neurotherapeutics*, *10*(9), 1449–1466.

- Givogri, M. I., Galbiati, F., Fasano, S., Amadio, S., Perani, L., & Superchi, D., et al. (2006). Oligodendroglial progenitor cell therapy limits central neurological deficits in mice with metachromatic leukodystrophy. *Journal of Neuroscience*, *26*(12), 3109–3119.
- Givogri, M. I., Bottai, D., Zhu, H. L., Fasano, S., Lamorte, G., & Brambilla, R., et al. (2008). Multipotential neural precursors transplanted into the metachromatic leukodystrophy brain fail to generate oligodendrocytes but contribute to limit brain dysfunction. *Developmental Neuroscience*, *30*(5), 340–357.
- Goebel, H. H. (1995). The neuronal ceroid-lipofuscinoses. *Journal of Child Neurology*, *10*(6), 424–437.
- Gressens, P. (2006). Pathogenesis of migration disorders. *Current Opinion in Neurology*, *19*(2), 135–140.
- Grunnet, M. L., & Spilsbury, P. R. (1973). The central nervous system in Fabry's disease. An ultrastructural study. *Archives of Neurology*, *28*(4), 231–234.
- Haltia, M. (2006). The neuronal ceroid-lipofuscinoses: From past to present. *Biochimica et Biophysica Acta*, *1762*(10), 850–856.
- Haymond, M. W., & Sunehag, A. L. (2003). Hypoglycemia. In A. M. R. C. D. Rudolph, M. K. Hostetter, G. Lister & N. J. Siegel (Eds.), *Pediatrics* (pp. 2106–2111). New York: McGraw-Hill.
- Hess, B., Saftig, P., Hartmann, D., Coenen, R., Lullmann-Rauch, R., & Goebel, H. H., et al. (1996). Phenotype of arylsulfatase A-deficient mice: Relationship to human metachromatic leukodystrophy. *Proceedings of the National Academy of Sciences of the United States of America*, *93*(25), 14821–14826.
- Hickman, S., & Neufeld, E. F. (1972). A hypothesis for I-cell disease: Defective hydrolases that

- do not enter lysosomes. *Biochemical and Biophysical Research communications*, 49(4), 992–999.
- Hickman, S., Shapiro, L. J., & Neufeld, E. F. (1974). A recognition marker required for uptake of a lysosomal enzyme by cultured fibroblasts. *Biochemical and Biophysical Research communications*, 57(1), 55–61.
- Hoogerbrugge, P. M., Poorthuis, B. J., Wagemaker, G., van Bakkum, D. W., & Suzuki, K. (1989). Alleviation of neurologic symptoms after bone marrow transplantation in twitcher mice. *Transplantation Proceedings*, 21(1 Pt 3), 2980–2981.
- Horvath, R., et al. (2009). Molecular basis of infantile reversible cytochrome c oxidase deficiency. *Brain*, 132, 3165–3174.
- Igisu, H., & Suzuki, K. (1984). Progressive accumulation of toxic metabolite in a genetic leukodystrophy. *Science*, 224(4650), 753–755.
- Jacobs, H. T., & Turnbull, D. M. (2005). Nuclear genes and mitochondrial translation: A new class of genetic disease. *Trends in Genet*, 21, 312–314.
- Janssen, A., Gressens, P., Grabenbauer, M., Baumgart, E., Schad, A., & Vanhorebeek, I., et al. (2003). Neuronal migration depends on intact peroxisomal function in brain and in extraneuronal tissues. *Journal of Neuroscience*, 23(30), 9732–9741.
- Jatana, M., Giri, S., & Singh, A. K. (2002). Apoptotic positive cells in Krabbe brain and induction of apoptosis in rat C6 glial cells by psychosine. *Neuroscience Letters*, 330(2), 183–187.
- Kishnani, P. S., Corzo, D., Nicolino, M., Byrne, B., Mandel, H., & Hwu, W. L., et al. (2007). Recombinant human acid [alpha]-glucosidase: Major clinical benefits in infantile-onset Pompe disease. *Neurology*, 68(2), 99–109.

- Krivit, W., Sung, J. H., Shapiro, E. G., & Lockman, L. A. (1995). Microglia: The effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. *Cell Transplant*, *4*(4), 385–392.
- Krivit, W., Shapiro, E. G., Peters, C., Wagner, J. E., Cornu, G., & Kurtzberg, J., et al. (1998). Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy. *The New England Journal of Medicine*, *338*(16), 1119–1126.
- Krivit, W., Peters, C., & Shapiro, E. G. (1999). Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. *Current Opinion in Neurology*, *12*(2), 167–176.
- Lamhonwah, A. M., Olpin, S. E., Pollitt, R. J., Vianey-Saban, C., Divry, P., & Guffon, N., et al. (2002). Novel OCTN2 mutations: No genotype-phenotype correlations: Early carnitine therapy prevents cardiomyopathy. *American Journal of Medical Genetics Part A*, *111*(3), 271–284.
- Lamhonwah, A. M., Olpin, S. E., Pollitt, R. J., Vianey-Saban, C., Divry, P., & Guffon, N., et al. (2007). Clinical results of enzyme replacement therapy in Fabry disease: A comprehensive review of literature. *International Journal of Clinical Practice*, *61*(2), 293–302.
- Luca, T., Givogri, M. I., Perani, L., Galbiati, F., Follenzi, A., & Naldini, L., et al. (2005). Axons mediate the distribution of arylsulfatase A within the mouse hippocampus upon gene delivery. *Molecular Therapy*, *12*(4), 669–679.
- Lucia, A., Smith, L., Naidoo, M., Gonzalez-Freire, M., Perez, M., & Rubio, J. C., et al. (2008).

- McArdle disease: Another systemic low-inflammation disorder? *Neuroscience Letters*, 431(2), 106–111.
- Malm, G., Ringden, O., Winiarski, J., Grondahl, E., Uyebrant, P., & Eriksson, U., et al. (1996). Clinical outcome in four children with metachromatic leukodystrophy treated by bone marrow transplantation. *Bone Marrow Transplant*, 17(6), 1003–1008.
- Matzner, U., Habetha, M., & Gieselmann, V. (2000). Retrovirally expressed human arylsulfatase A corrects the metabolic defect of arylsulfatase A-deficient mouse cells. *Gene Therapy*, 7(9), 805–812.
- Matzner, U., Hartmann, D., Lullmann-Rauch, R., Coenen, R., Rothert, F., & Mansson, J. E., et al. (2002). Bone marrow stem cell-based gene transfer in a mouse model for metachromatic leukodystrophy: Effects on visceral and nervous system disease manifestations. *Gene Therapy*, 9(1), 53–63.
- Matzner, U., et al. (2005). Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. *Human Molecular Genetics*, 14(9), 1139–1152.
- McCue, M. E., Valberg, S. J., Miller, M. B., Wade, C., DiMauro, S., & Akman, H. O., et al. (2008). Glycogen synthase (GYS1) mutation causes a novel skeletal muscle glycogenosis. *Genomics*, 91, 458–466.
- Medin, J. A., Takenaka, T., Carpentier, S., Garcia, V., Basile, J. P., & Segui, B., et al. (1999). Retrovirus-mediated correction of the metabolic defect in cultured Farber disease cells. *Human Gene Therapy*, 10(8), 1321–1329.
- Meikle, P. J., Hopwood, J. J., Clague, A. E., & Carey, W. F. (1999). Prevalence of lysosomal storage disorders. *JAMA*, 281(3), 249–254.

- Miyatake, T. (1969). A study on glycolipids in Fabry's disease. *Japanese Journal of Experimental Medicine*, 39(1), 35–45.
- Miyatake, T., & Suzuki, K. (1973). Additional deficiency of psychosine galactosidase in globoid cell leukodystrophy: An implication to enzyme replacement therapy. *Birth Defects Original Article Series*, 9(2), 136–140.
- Moser, H. W., & Moser, A. B. (1996). Very long-chain fatty acids in diagnosis, pathogenesis, and therapy of peroxisomal disorders. *Lipids*, 31(Suppl.), S141–S144.
- Moser, H. W., Bergin, A., & Cornblath, D. (1991). Peroxisomal disorders. *Biochemistry and Cell Biology*, 69(7), 463–474.
- Naidu, S., & Moser, H. W. (1990). Peroxisomal disorders. *Neurologic Clinics*, 8(3), 507–528.
- Oezen, I., Rossmannith, W., Forss-Petter, S., Kemp, S., Voigtlander, T., & Moser-Thier, K., et al. (2005). Accumulation of very long-chain fatty acids does not affect mitochondrial function in adrenoleukodystrophy protein deficiency. *Human Molecular Genetics*, 14(9), 1127–1137.
- Ohkuma, A., Noguchi, S., Sugie, H., Malicdan, M. C., Fukuda, T., & Shimazu, K., et al. (2009). Clinical and genetic analysis of lipid storage myopathies. *Muscle and Nerve*, 39, 333–342.
- Osher, E., Fattal-Valevski, A., Sagie, L., Urshanski, N., Amir-Levi, Y., & Katzburg, S., et al. (2010). Pyrimethamine increases beta-hexosaminidase A activity in patients with Late Onset Tay Sachs. *Molecular Genetics and Metabolism*.
- Peters, C., & Steward, C. G. (2003). Hematopoietic cell transplantation for inherited metabolic diseases: An overview of outcomes and practice guidelines. *Bone Marrow Transplant*, 31(4), 229–239.

- Platt, F. M., & Walkley, S. U. (2004). *Lysosomal disorders of the brain*. New York: Oxford University Press.
- Platt, F. M., Neises, G. R., Reinkensmeier, G., Townsend, M. J., Perry, V. H., & Proia, R. L., et al. (1997). Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. *Science*, *276*(5311), 428–431.
- Powers, J. M. (1995). The pathology of peroxisomal disorders with pathogenetic considerations. *Journal of Neuropathology and Experimental Neurology*, *54*(5), 710–719.
- Purpura, D. P., & Suzuki, K. (1976). Distortion of neuronal geometry and formation of aberrant synapses in neuronal storage disease. *Brain Research*, *116*(1), 1–21.
- Quinzii, C. M., & Hirano, M. (2010). Coenzyme Q and mitochondrial disease. *Developmental Disabilities Research Reviews*, *16*(2), 183–188.
- Ramachandran, N., Girard, J. M., Turnbull, J., & Minassian, B. A. (2009). The autosomal recessively inherited progressive myoclonus epilepsies and their genes. *Epilepsia*, *50*(Suppl. 5), 29–36.
- Ramsubir, S., Nonaka, T., Girbes, C. B., Carpentier, S., Levade, T., & Medin, J. A. (2008). *In vivo* delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease. *Molecular Genetics and Metabolism*, *95*(3), 133–141.
- Rhodin, J. (1954). Correlation of ultrastructure organization and function in normal and experimentally treated proximal convoluted tubule cells of the mouse kidney. Doctoral Thesis., in Karolinska Institute. Stockhom.
- Ringden, O., Groth, C. G., Erikson, A., Granqvist, S., Mansson, J. E., & Sparrelid, E. (1995). Ten years' experience of bone marrow transplantation for Gaucher disease.

Transplantation, 59(6), 864–870.

Samuels, S., Korey, S. R., Gonatas, J., Terry, R. D., & Weiss, M. (1963). Studies in Tay-Sachs disease. IV. Membranous cytoplasmic bodies. *Journal of Neuropathology and Experimental Neurology*, 22, 81–97.

Saravanan, K., Schaeren-Wiemers, N., Klein, D., Sandhoff, R., Schwarz, A., & Yaghoofam, A., et al. (2004). Specific downregulation and mistargeting of the lipid raft-associated protein MAL in a glycolipid storage disorder. *Neurobiology of Disease*, 16(2), 396–406.

Schibanoff, J. M., Kamoshita, S., & O'Brien, J. S. (1969). Tissue distribution of glycosphingolipids in a case of Fabry's disease. *Journal of Lipid Research*, 10(5), 515–520.

Schneiderman, J., Thormann, K., Charrow, J., & Kletzel, M. (2007). Correction of enzyme levels with allogeneic hematopoietic progenitor cell transplantation in Niemann-Pick type B. *Pediatric Blood & Cancer*, 49(7), 987–989.

Schuchman, E. H. (2007). The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. *Journal of Inherited Metabolic Disease*, 30(5), 654–663.

Scriver, C. R. (Ed.). (2001). *The metabolic and molecular bases of inherited diseases* (8th ed.). New York: McGraw-Hill.

Shah, A. J., Kapoor, N., Crooks, G. M., Parkman, R., Weinberg, K. I., & Wilson, K., et al. (2005). Successful hematopoietic stem cell transplantation for Niemann-Pick disease type B. *Pediatrics*, 116(4), 1022–1025.

Shimozawa, N. (2007). Molecular and clinical aspects of peroxisomal diseases. *Journal of Inherited Metabolic Disease*, 30(2), 193–197.

Spiegel, R., Gomez, E. A., Akman, H. O., Krishna, S., Horovitz, Y., & DiMauro, S. (2009).

- Myopathic form of phosphoglycerate kinase (PGK) deficiency: A new case and pathogenic considerations. *Neuromuscular Disorders*, 19, 207–211.
- Spinazzola, A., Invernizzi, F., Carrara, F., Lamantea, E., Donati, A., & Dirocco, M., et al. (2009). Clinical and molecular features of mitochondrial DNA depletion syndromes. *Journal of Inherited Metabolic Disease*, 32: 143–158.
- Steinberg, S. J., Dodt, G., Raymond, G. V., Braverman, N. E., Moser, A. B., & Moser, H. W. (2006). Peroxisome biogenesis disorders. *Biochimica et Biophysica Acta*, 1763(12), 1733–1748.
- Sugita, M., Dulaney, J. T., & Moser, H. W. (1972). Ceramidase deficiency in Farber's disease (lipogranulomatosis). *Science*, 178(65), 1100–1102.
- Sung, J. H. (1979). Autonomic neurons affected by lipid storage in the spinal cord in Fabry's disease: Distribution of autonomic neurons in the sacral cord. *Journal of Neuropathology and Experimental Neurology*, 38(2), 87–98.
- Suzuki, K. (1998). Twenty-five years of the “psychosine hypothesis”: A personal perspective of its history and present status. *Neurochem Res*, 23(3), 251–259.
- Terry, R. D., & Korey, S. R. (1960). Membranous cytoplasmic granules in infantile amaurotic idiocy. *Nature*, 188, 1000–1002.
- Van Veldhoven, P. P. (2010). Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism. *Journal of Lipid Research*, 51(10), 2863–2895.
- Vanier, M. T., & Millat, G. (2003). Niemann-Pick disease type C. *Clin Genet*, 64(4), 269–281.
- Vormoor, J., Ehlert, K., Groll, A. H., Koch, H. G., Frosch, M., & Roth, J. (2004). Successful hematopoietic stem cell transplantation in Farber disease. *J Pediatr*, 144(1), 132–134.

- Vos, J. P., Lopes-Cardozo, M., & Gadella, B. M. (1994). Metabolic and functional aspects of sulfogalactolipids. *Biochimica et Biophysica Acta*, 1211(2), 125–149.
- Wanders, R. J., & Tager, J. M. (1998). Lipid metabolism in peroxisomes in relation to human disease. *Mol Aspects Med*, 19(2), 69–154.
- Wanders, R. J., & Waterham, H. R. (2006). Peroxisomal disorders: The single peroxisomal enzyme deficiencies. *Biochimica et Biophysica Acta*, 1763(12), 1707–1720.
- Wang, D., Yang, H., De Braganca, K. C., Lu, J., Yu Shih, L., & Briones, P., et al. (2008). The molecular basis of pyruvate carboxylase deficiency: Mosaicism correlates with prolonged survival. *Molecular Genetics and Metabolism*, 95(1–2), 31–38.
- White, A. B., Givogri, M. I., Lopez-Rosas, A., Cao, H., van Breemen, R., & Thinakaran, G., et al. (2009). Psychosine accumulates in membrane microdomains in the brain of krabbe patients, disrupting the raft architecture. *Journal of Neuroscience*, 29(19), 6068–6077.
- White, A. B., Galbiati, F., Givogri, M. I., Lopez Rosas, A., Qiu, X., & van Breemen, R., et al. (2011). Persistence of psychosine in brain lipid rafts is a limiting factor in the therapeutic recovery of a mouse model for Krabbe disease. *Journal of Neuroscience Research*, 89(3), 352–364.
- Yamada, H., Martin, P., & Suzuki, K. (1996). Impairment of protein kinase C activity in twitcher Schwann cells *in vitro*. *Brain Research*, 718(1–2), 138–144.
- Zaka, M., & Wenger, D. A. (2004). Psychosine-induced apoptosis in a mouse oligodendrocyte progenitor cell line is mediated by caspase activation. *Neuroscience Letters*, 358(3), 205–209.
- Zheng, W., Padia, J., Urban, D. J., Jadhav, A., Goker-Alpan, O., & Simeonov, A., et al. (2007).

Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. *Proceedings of the National Academy of Sciences of the United States of America*, 104(32), 13192–13197.

van Zyl, R., Gieselmann, V., & Eckhardt, M. (2010). Elevated sulfatide levels in neurons cause lethal audiogenic seizures in mice. *Journal of Neurochemistry*, 112(1), 282–295.